Form 4 - Statement of changes in beneficial ownership of securities:
SEC Accession No. 0001213900-13-007396
Filing Date
2013-12-24
Accepted
2013-12-24 15:41:33
Documents
1
Period of Report
2013-08-08

Document Format Files

Seq Description Document Type Size
1 OWNERSHIP DOCUMENT f4080813traversa_actinium.html 4  
1 OWNERSHIP DOCUMENT f4080813traversa_actinium.xml 4 5713
  Complete submission text file 0001213900-13-007396.txt   7141
Mailing Address 501 FIFTH AVENUE, 3RD FLOOR NEW YORK NY 10017
Business Address 501 FIFTH AVENUE, 3RD FLOOR NEW YORK NY 10017 212-300-2131
Actinium Pharmaceuticals, Inc. (Issuer) CIK: 0001388320 (see all company filings)

EIN.: 880378336 | State of Incorp.: DE | Fiscal Year End: 1231
SIC: 6770 Blank Checks

Mailing Address 138 CANTERBURY LN BLUE BELL PA 19422
Business Address
TRAVERSA SERGIO (Reporting) CIK: 0001565832 (see all company filings)

Type: 4 | Act: 34 | File No.: 000-52446 | Film No.: 131297633